DE60015370D1 - Injizierbare buprenorphinhaltige mikrosphärenzusammensetzungen und ihre verwendung zur reduktion von heroin- und alkoholkonsum - Google Patents

Injizierbare buprenorphinhaltige mikrosphärenzusammensetzungen und ihre verwendung zur reduktion von heroin- und alkoholkonsum

Info

Publication number
DE60015370D1
DE60015370D1 DE60015370T DE60015370T DE60015370D1 DE 60015370 D1 DE60015370 D1 DE 60015370D1 DE 60015370 T DE60015370 T DE 60015370T DE 60015370 T DE60015370 T DE 60015370T DE 60015370 D1 DE60015370 D1 DE 60015370D1
Authority
DE
Germany
Prior art keywords
methadone
microspheric
compositions
alcohol consumption
partial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60015370T
Other languages
English (en)
Other versions
DE60015370T2 (de
Inventor
R Tice
K Staas
M Ferrell
Peter Markland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Surmodics Pharmaceuticals Inc
Original Assignee
SOUTHERN RES INST BIRMINGHAM
Southern Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SOUTHERN RES INST BIRMINGHAM, Southern Research Institute filed Critical SOUTHERN RES INST BIRMINGHAM
Publication of DE60015370D1 publication Critical patent/DE60015370D1/de
Application granted granted Critical
Publication of DE60015370T2 publication Critical patent/DE60015370T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
DE60015370T 1999-08-27 2000-08-25 Injizierbare buprenorphinhaltige mikrosphärenzusammensetzungen und ihre verwendung zur reduktion von heroin- und alkoholkonsum Expired - Lifetime DE60015370T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15111299P 1999-08-27 1999-08-27
US151112P 1999-08-27
PCT/US2000/023390 WO2001015699A1 (en) 1999-08-27 2000-08-25 Injectable buprenorphine microparticle compositions and their use

Publications (2)

Publication Number Publication Date
DE60015370D1 true DE60015370D1 (de) 2004-12-02
DE60015370T2 DE60015370T2 (de) 2006-03-09

Family

ID=22537367

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60015370T Expired - Lifetime DE60015370T2 (de) 1999-08-27 2000-08-25 Injizierbare buprenorphinhaltige mikrosphärenzusammensetzungen und ihre verwendung zur reduktion von heroin- und alkoholkonsum

Country Status (24)

Country Link
US (2) US6495155B1 (de)
EP (1) EP1212061B1 (de)
JP (1) JP4913298B2 (de)
KR (1) KR100730440B1 (de)
CN (2) CN100387228C (de)
AT (1) ATE280579T1 (de)
AU (1) AU765496C (de)
BR (1) BR0013650A (de)
CA (1) CA2382577C (de)
CY (1) CY1106043T1 (de)
CZ (1) CZ2002728A3 (de)
DE (1) DE60015370T2 (de)
EA (1) EA009080B1 (de)
ES (1) ES2230154T3 (de)
HK (1) HK1046858B (de)
HU (1) HUP0203613A3 (de)
IL (2) IL148343A0 (de)
MX (1) MXPA02002105A (de)
NO (2) NO322650B1 (de)
NZ (1) NZ517997A (de)
PL (1) PL198334B1 (de)
PT (1) PT1212061E (de)
RO (1) RO121631B1 (de)
WO (1) WO2001015699A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2230154T3 (es) * 1999-08-27 2005-05-01 Southern Research Institute Composiciones inyectables de buprenorfina y su utilizacion para reduccion del consumo de heroina y alcohol.
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
EP1411861B1 (de) * 2001-06-29 2012-04-04 Medgraft Microtech, Inc. Biologisch abbaubare injizierbare implantate und verwandte herstellungs- und verwendungsmethoden
US20030003113A1 (en) * 2001-06-29 2003-01-02 Lewandowski Leon J. Individualized addiction cessation therapy
EP2311460A1 (de) 2001-07-06 2011-04-20 Endo Pharmaceuticals Inc. Kontrolliert freisetzende Formulierungen von Oxymorphon
EP1404331B1 (de) * 2001-07-06 2007-10-31 Penwest Pharmaceuticals Co. Verzögert freisetzende formulierungen von oxymorphon
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
CA2459976A1 (en) * 2001-09-26 2003-04-03 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
US7462366B2 (en) 2002-03-29 2008-12-09 Boston Scientific Scimed, Inc. Drug delivery particle
US7041320B1 (en) * 2002-05-31 2006-05-09 Biotek, Inc. High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence
WO2003101358A1 (en) 2002-05-31 2003-12-11 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
US7842377B2 (en) * 2003-08-08 2010-11-30 Boston Scientific Scimed, Inc. Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US8012454B2 (en) 2002-08-30 2011-09-06 Boston Scientific Scimed, Inc. Embolization
US7883490B2 (en) 2002-10-23 2011-02-08 Boston Scientific Scimed, Inc. Mixing and delivery of therapeutic compositions
WO2004078178A1 (en) * 2003-03-03 2004-09-16 Markus Heilig Buprenorphine compounds for treatment of alcohol dependence and excessive alcohol use
ZA200507877B (en) 2003-03-31 2007-01-31 Titan Pharmaceuticals Inc Implantable polymeric device for sustained release of dopamine agonist
US7976823B2 (en) 2003-08-29 2011-07-12 Boston Scientific Scimed, Inc. Ferromagnetic particles and methods
US7901770B2 (en) 2003-11-04 2011-03-08 Boston Scientific Scimed, Inc. Embolic compositions
US7736671B2 (en) 2004-03-02 2010-06-15 Boston Scientific Scimed, Inc. Embolization
US8173176B2 (en) 2004-03-30 2012-05-08 Boston Scientific Scimed, Inc. Embolization
US7919499B2 (en) * 2004-04-22 2011-04-05 Alkermes, Inc. Naltrexone long acting formulations and methods of use
FR2869801B1 (fr) * 2004-05-05 2008-09-12 Ethypharm Sa Procede de preparation de compositions a liberation prolongee et utilisation de ces compositions pour le traitement des affections chroniques du systeme nerveux central (snc)
US7311861B2 (en) 2004-06-01 2007-12-25 Boston Scientific Scimed, Inc. Embolization
NZ582130A (en) 2004-08-04 2011-11-25 Clinuvel Pharmaceuticals Ltd Methods of inducing melanogenesis in a subject
US7858183B2 (en) 2005-03-02 2010-12-28 Boston Scientific Scimed, Inc. Particles
US7727555B2 (en) 2005-03-02 2010-06-01 Boston Scientific Scimed, Inc. Particles
US7963287B2 (en) 2005-04-28 2011-06-21 Boston Scientific Scimed, Inc. Tissue-treatment methods
US9463426B2 (en) 2005-06-24 2016-10-11 Boston Scientific Scimed, Inc. Methods and systems for coating particles
US20070141160A1 (en) * 2005-12-15 2007-06-21 Brown Laura J Method of treatment for osteoarthritis by local intra-articular injection of microparticles
US7947368B2 (en) 2005-12-21 2011-05-24 Boston Scientific Scimed, Inc. Block copolymer particles
WO2008106571A2 (en) * 2007-02-28 2008-09-04 Abbott Laboratories Sustained release parenteral formulations of buprenorphine
KR101545874B1 (ko) * 2007-09-03 2015-08-20 나노테라퓨틱스, 인코포레이티드 난용성 약물의 전달을 위한 입상 조성물
ES2718612T3 (es) * 2007-12-20 2019-07-03 Evonik Corp Procedimiento para preparar micropartículas que tienen un bajo volumen de disolvente residual
CN104984343B (zh) * 2008-09-24 2019-04-02 赢创罗姆有限公司 耐受乙醇影响的非阿片类药物的pH依赖性受控释放的药物组合物
CN102164589A (zh) 2008-09-24 2011-08-24 赢创罗姆有限公司 耐受乙醇影响的非阿片类药物的pH依赖性受控释放的药物组合物
JP5453433B2 (ja) * 2008-09-24 2014-03-26 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング エタノールの影響に対する耐性を有するｐＨ依存の制御放出の医薬オピオイド組成物
US20100268191A1 (en) * 2009-04-21 2010-10-21 Medtronic Vascular, Inc. Drug Delivery Catheter using Frangible Microcapsules and Delivery Method
US9125867B2 (en) 2010-02-24 2015-09-08 Invincible Biotechnology Diversion- and/or abuse-resistant compositions and methods for making the same
US9272044B2 (en) * 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) * 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
WO2013126552A1 (en) 2012-02-21 2013-08-29 Auburn University Buprenorphine nanoparticle composition and methods thereof
CN110101702A (zh) 2012-04-17 2019-08-09 普渡制药公司 用于治疗阿片样物质所致不良药效学响应的系统和方法
CN102836131A (zh) * 2012-09-28 2012-12-26 山东大学 丁丙诺啡皮下注射用缓释微球制剂及其制备方法
US9636308B2 (en) 2013-03-15 2017-05-02 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
US9393211B2 (en) * 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
JP6135292B2 (ja) * 2013-05-10 2017-05-31 ニプロ株式会社 マイクロカプセル製剤の製造方法
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CA3015557C (en) 2014-11-07 2019-07-16 Indivior Uk Limited The use of sustained-release buprenorphine formulations for the treatment of pain or opioid use disorders
WO2017147285A1 (en) 2016-02-23 2017-08-31 Biodelivery Sciences International, Inc. Sustained release buprenorphine microspheres (srbm) and methods of use thereof
HUE060906T2 (hu) 2016-09-13 2023-04-28 Alar Pharmaceuticals Inc Nyújtott felszabadulású buprenorfin-készítmények
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
CA3150767A1 (en) * 2019-08-12 2021-02-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Pharmaceutical compositions comprising a combination of opioid antagonists

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4530840A (en) * 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4568559A (en) 1984-02-06 1986-02-04 Biotek, Inc. Composite core coated microparticles and process of preparing same
US4623588A (en) 1984-02-06 1986-11-18 Biotek, Inc. Controlled release composite core coated microparticles
GB8430346D0 (en) * 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
US5143661A (en) * 1987-05-26 1992-09-01 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules
FR2618674B1 (fr) 1987-07-30 1990-06-15 Ire Celltarg Sa Microparticules comportant un polymere biodegradable controlant la liberation d'un principe actif antimalarique, compositions pharmaceutiques en comprenant et procede de preparation
GB8728294D0 (en) 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US4902515A (en) * 1988-04-28 1990-02-20 E. I. Dupont De Nemours And Company Polylactide compositions
US5702716A (en) * 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
DE69024953T3 (de) 1989-05-04 2005-01-27 Southern Research Institute, Birmingham Einkapselungsverfahren
US5486362A (en) 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
AU2605592A (en) * 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5633000A (en) 1994-06-23 1997-05-27 Axxia Technologies Subcutaneous implant
US5716631A (en) 1995-09-29 1998-02-10 Rdn Therapeutics Inc. Long acting narcotic analgesics and antagonists
US5919473A (en) * 1997-05-12 1999-07-06 Elkhoury; George F. Methods and devices for delivering opioid analgesics to wounds via a subdermal implant
ES2230154T3 (es) * 1999-08-27 2005-05-01 Southern Research Institute Composiciones inyectables de buprenorfina y su utilizacion para reduccion del consumo de heroina y alcohol.

Also Published As

Publication number Publication date
NO322650B1 (no) 2006-11-13
IL148343A (en) 2008-03-20
KR100730440B1 (ko) 2007-06-19
NZ517997A (en) 2002-11-26
US7473431B2 (en) 2009-01-06
CA2382577C (en) 2008-01-22
ATE280579T1 (de) 2004-11-15
HUP0203613A2 (hu) 2003-02-28
CY1106043T1 (el) 2011-04-06
AU765496B2 (en) 2003-09-18
AU7075100A (en) 2001-03-26
HK1046858B (zh) 2005-03-24
CN1248689C (zh) 2006-04-05
CZ2002728A3 (cs) 2002-08-14
BR0013650A (pt) 2002-05-07
EP1212061A1 (de) 2002-06-12
RO121631B1 (ro) 2008-01-30
AU765496C (en) 2005-08-25
PL354977A1 (en) 2004-03-22
NO20020924D0 (no) 2002-02-26
HK1046858A1 (en) 2003-01-30
US6495155B1 (en) 2002-12-17
ES2230154T3 (es) 2005-05-01
CA2382577A1 (en) 2001-03-08
NO20020924L (no) 2002-04-03
CN1788721A (zh) 2006-06-21
KR20020053057A (ko) 2002-07-04
JP2003508439A (ja) 2003-03-04
JP4913298B2 (ja) 2012-04-11
EP1212061B1 (de) 2004-10-27
CN100387228C (zh) 2008-05-14
EA009080B1 (ru) 2007-10-26
HUP0203613A3 (en) 2005-01-28
EA200200295A1 (ru) 2002-08-29
CN1382051A (zh) 2002-11-27
WO2001015699A1 (en) 2001-03-08
IL148343A0 (en) 2002-09-12
US20030152638A1 (en) 2003-08-14
DE60015370T2 (de) 2006-03-09
NO20063239L (no) 2002-04-03
PT1212061E (pt) 2005-01-31
PL198334B1 (pl) 2008-06-30
MXPA02002105A (es) 2003-12-11

Similar Documents

Publication Publication Date Title
DE60015370D1 (de) Injizierbare buprenorphinhaltige mikrosphärenzusammensetzungen und ihre verwendung zur reduktion von heroin- und alkoholkonsum
DE60009477D1 (de) Injizierbare naltrexon mikrosphären zusammensetzungen und ihre verwendung zur reduktion von heroin- und alkoholkonsum
Frenk Pro-and anticonvulsant actions of morphine and the endogenous opioids: involvement and interactions of multiple opiate and non-opiate systems
AU2003304238A1 (en) Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
Endoh et al. Characterization of the antinociceptive effects of TRK-820 in the rat
EP1555023A3 (de) Injizierbare Buprenorphin-Mikropartikelformulierung und ihre Verwendung
Bidlack et al. Partial opioids: medications for the treatment of pain and drug abuse
ATE287265T1 (de) Verwendung von schwachen opioiden und gemischten opioidagonisten / -antagonisten zur therapie der harninkontinenz
Wettstein et al. Opioid antagonist profile of SC nor-binaltorphimine in the formalin paw assay
Lattanzi et al. HS‐599: a novel long acting opioid analgesic does not induce place‐preference in rats
Briggs et al. Kappa antinociceptive activity of spiradoline in the cold-water tail-flick assay in rats
Tseng et al. Spinal δ2 but not δ1 opioid receptors are involved in intracereboventricular β-endorphin-induced antinociception in the mouse
Jarema et al. Acute and chronic effects of morphine under a progressive-ratio 25 schedule of food delivery
AU9266698A (en) Acidic addition salts of morphine alkaloids and the application thereof
OELTGEN Characterization and utilization of opiate-like hibernation factors(Report, 15 Jul. 1992- 15 Dec. 1993)
Campi et al. ZT 52656A: EEG spectral analysis in freely-moving rats
Paquette Kappa-opioid induced regulation of mu-opioid mediated effects on EEG power spectra and behavior in rats.
Porchet et al. Pharmacokinetic and pharmacodynamic modelling of clonidine induced analgesia and influence of a meal
AUPS010302A0 (en) Subcutaneous implant or injection combining opiate agonists and antagonists

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BROOKWOOD PHARMACEUTICALS INC., BIRMINGHAM, ALA.,

8328 Change in the person/name/address of the agent

Representative=s name: WEICKMANN & WEICKMANN, 81679 MUENCHEN

8328 Change in the person/name/address of the agent

Representative=s name: HOEFER & PARTNER, 81543 MUENCHEN